Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Сахарный диабет и патология почек: преимущества терапии, основанной на инкретинах
Сахарный диабет и патология почек: преимущества терапии, основанной на инкретинах
Шестакова М.В., Шамхалова М.Ш. Сахарный диабет и патология почек: преимущества терапии, основанной на инкретинах. Consilium Medicum. 2013; 15 (4): 10–14.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. М.: МИА, 2009.
2. Сахарный диабет: острые и хронические осложнения. Под ред. И.И.Дедова, М.В.Шестаковой, М.: МИА, 2011.
3. Маслова О.В., Сунцов Ю.И., Шестакова М.В. и др. Распространенность диабетической нефропатии и хронической болезни почек при сахарном диабете в Российской Федерации. Клин. нефрология. 2010; 3: 45–50.
4. NKF-K/DOKI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S17–S31.
5. Moen MF, Zhan M, Hsu VD et al. Clin J Am Soc Nephrol; 2009. Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease; Clin J Am Soc Nephrol 2009; 4 (6): 1121–7.
6. Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920–7.
7. Drechsler C, Krane V, Ritz E et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009; 120: 2421–8.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 2007; 356: 2457–71.
9. Ramirez SP, Albert JM, Blayney MJ. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20: 1094–101.
10. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
11. Klonoff DC, Buse JB, Nielsen LL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275–86.
12. Linnebjerg H, Kothare PA, Park S. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317–27.
13. Jacobsen LV, Hindsberger C, Robson R. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009; 68: 898–905.
14. Januvia (sitagliptin) prescribing information. Whitehouse Station, NJ, Merck & Co, Inc 2009.
15. Bergman AJ, Cote J, Yi B. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862–4.
16. Chan JCN, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesety and Metabolism 2008; 10: 545–55.
17. He H, Tran P, Yin H. Absorption, metabolism and excretion of vildagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Drug Metab Dispos 2009; 536–44.
18. Lukashevich V, Schweizer A, Shao Q et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-weeck randomized placebo-controlled trial. Diabetes Obes Metab 2011; 13: 947–54.
19. Onglyza (saxagliptin) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company and Wilmington, DE: AstraZeneca Pharmaceuticals LP 2009.
20. Nowicki M, Rychlik I, Haller H et al. Saxagliptin improves glycaemic control and is well tolerated in type 2 diabetes and renal impairment. Diabetes Obes Metab 2011; 13: 523–32.
21. Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13 (10): 939–46.
22. Freeman MK. Efficacy and safety of linagliptin (Tradjenta) in adults with type 2 diabetes. Pharmacy and Therapeutics 2011; 36: 807–12.
23. Cooper M, von Eynatten M, Emser A et al. Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes with or Without Renal Impairment: Results From a Global Phase 3 Program. American Diabetes Association, 71th Sci Sessions, San Diego 2011; p. 1068.
24. Sloan L, Newman J, Sauce C et al. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment. American Diabetes Association, 71th Sci Sessions, San Diego 2011; p. 413.
25. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism 2011; 13: 7–18.
2. Сахарный диабет: острые и хронические осложнения. Под ред. И.И.Дедова, М.В.Шестаковой, М.: МИА, 2011.
3. Маслова О.В., Сунцов Ю.И., Шестакова М.В. и др. Распространенность диабетической нефропатии и хронической болезни почек при сахарном диабете в Российской Федерации. Клин. нефрология. 2010; 3: 45–50.
4. NKF-K/DOKI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S17–S31.
5. Moen MF, Zhan M, Hsu VD et al. Clin J Am Soc Nephrol; 2009. Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease; Clin J Am Soc Nephrol 2009; 4 (6): 1121–7.
6. Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920–7.
7. Drechsler C, Krane V, Ritz E et al. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 2009; 120: 2421–8.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 2007; 356: 2457–71.
9. Ramirez SP, Albert JM, Blayney MJ. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 2009; 20: 1094–101.
10. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
11. Klonoff DC, Buse JB, Nielsen LL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275–86.
12. Linnebjerg H, Kothare PA, Park S. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317–27.
13. Jacobsen LV, Hindsberger C, Robson R. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009; 68: 898–905.
14. Januvia (sitagliptin) prescribing information. Whitehouse Station, NJ, Merck & Co, Inc 2009.
15. Bergman AJ, Cote J, Yi B. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862–4.
16. Chan JCN, Scott R, Arjona Ferreira JC et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesety and Metabolism 2008; 10: 545–55.
17. He H, Tran P, Yin H. Absorption, metabolism and excretion of vildagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Drug Metab Dispos 2009; 536–44.
18. Lukashevich V, Schweizer A, Shao Q et al. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-weeck randomized placebo-controlled trial. Diabetes Obes Metab 2011; 13: 947–54.
19. Onglyza (saxagliptin) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company and Wilmington, DE: AstraZeneca Pharmaceuticals LP 2009.
20. Nowicki M, Rychlik I, Haller H et al. Saxagliptin improves glycaemic control and is well tolerated in type 2 diabetes and renal impairment. Diabetes Obes Metab 2011; 13: 523–32.
21. Graefe-Mody U, Friedrich C, Port A et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13 (10): 939–46.
22. Freeman MK. Efficacy and safety of linagliptin (Tradjenta) in adults with type 2 diabetes. Pharmacy and Therapeutics 2011; 36: 807–12.
23. Cooper M, von Eynatten M, Emser A et al. Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes with or Without Renal Impairment: Results From a Global Phase 3 Program. American Diabetes Association, 71th Sci Sessions, San Diego 2011; p. 1068.
24. Sloan L, Newman J, Sauce C et al. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment. American Diabetes Association, 71th Sci Sessions, San Diego 2011; p. 413.
25. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism 2011; 13: 7–18.
Авторы
М.В.Шестакова, М.Ш.Шамхалова
ФГБУ Эндокринологический научный центр Минздрава РФ, Москва
ФГБУ Эндокринологический научный центр Минздрава РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.